

BioPharm Therapeutic Areas:
Tracking which area(s)
of pharmaceutical industry
subscribers can track.

THERAPEUTIC AREAS

Drill in to view a market overview, partnering opportunities, competitive intelligence and more.

Cancer

9339 Drugs	1631 Developers
40 Indications	569 Conditions

Hormonal Systems

• 2316 Drugs • 808 Developers
• 21 Indications • 360 Conditions

Cardiovascular

• 2822 Drugs • 831 Developers
• 19 Indications • 330 Conditions

Immune System

• 2925 Drugs • 1078 Developers
• 17 Indications • 361 Conditions

Central Nervous System

• 3941 Drugs • 1013 Developers
• 32 Indications • 409 Conditions

Infectious Diseases

• 5577 Drugs • 1379 Developers
• 51 Indications • 632 Conditions

Dermatology

• 1197 Drugs • 506 Developers
• 10 Indications • 164 Conditions

Musculoskeletal

• 1835 Drugs • 759 Developers
• 13 Indications • 234 Conditions

Gastrointestinal

• 1644 Drugs • 704 Developers
• 12 Indications • 247 Conditions

Nephrology

• 247 Drugs • 162 Developers
• 4 Indications • 45 Conditions

Genitourinary

• 896 Drugs • 335 Developers
• 15 Indications • 138 Conditions

Pain

• 1972 Drugs • 654 Developers
• 12 Indications • 183 Conditions

Hematological

• 1212 Drugs • 473 Developers
• 15 Indications • 215 Conditions

Respiratory

• 1171 Drugs • 420 Developers
• 9 Indications • 114 Conditions

Get Started - Customize your homepage

HOT TOPICS

- [Pre-Clinical Activity](#)
- [Biosimilar Drugs](#)
- [Emerging Markets](#)
- [Up and Coming Indications](#)
- [CRO Activity Analysis](#)

FEATURED REPORTS



Horizant Adverse Events Report

GSK/XenoPort's postherpetic neuralgia and restless legs syndrome drug Horizant received 184 adverse events.



Onglyza and Kombiglyze XR Adverse Events Report

AstraZeneca's Onglyza/Kombiglyze XR receives 19 reports of cardiac failure.



Horizant Adverse Events Report



Onglyza and Kombiglyze XR Adverse Events Report

BioPharm Insight

Hi, Andrew [Sign out](#)



Get started - [customize your page](#)

Mixed Receptive-Expressive Language Disorder

93392 Drugs

- 1631 Developers
- 40 Indications
- 569 Conditions

Cancer

- 9439 Drugs
- 1631 Developers
- 40 Indications
- 695 Conditions

Hot Topics

- Pre-Clinical Activity
- Biosimilar Drugs
- BRIC Markets
- Up and Coming Indications
- CRO Activity Analysis

Non-Phenylketonuric Hyperphenylalaninemia

- 2822 Drugs
- 831 Developers
- 19 Indications
- 330 Conditions

Hormonal Systems

- 2316 Drugs
- 1078 Developers
- 17 Indications
- 360 Conditions

Featured report

Horizant Adverse Events Report

GSK/XenoPort's postherpetic neuralgia and restless legs syndrome drug Horizant received 184 adverse events.



Cardiovascular

- 2822 Drugs
- 831 Developers
- 19 Indications
- 409 Conditions

Immune System

- 2925 Drugs
- 1078 Developers
- 17 Indications
- 362 Conditions

Featured report

Onglyza and Kombiglyze XR Adverse Events Report

AstraZeneca's Onglyza/Kombiglyze XR receives 19 reports of cardiac failure.



Central Nervous System

- 3941 Drugs
- 1013 Developers
- 32 Indications
- 409 Conditions


Infectious Diseases

- 5577 Drugs
- 1379 Developers
- 51 Indications
- 632 Conditions

Featured report

Novartis reports lung cancer patients respond to drug in study

Non-small cell lung cancer had responded to the treatment.



Dermatology

- 1197 Drugs
- 506 Developers
- 13 Indications
- 164 Conditions


Musculoskeletal

- 1835 Drugs
- 759 Developers
- 17 Indications
- 234 Conditions

Featured report

Clovis reports positive results for cancer drug

Biopharma Clovis Oncology Inc. is reporting positive findings midway through a study of a lung-cancer treatment.



Gastrointestinal

- 1644 Drugs
- 704 Developers
- 12 Indications
- 247 Conditions

Nephrology

- 247 Drugs
- 162 Developers
- 4 Indications
- 45 Conditions

Genitourinary

- 896 Drugs
- 335 Developers
- 15 Indications
- 138 Conditions

Hematological

- 1212 Drugs
- 473 Developers
- 15 Indications
- 215 Conditions

[Modify alerts](#) · [Unsubscribe](#) · [Feedback](#)



[Get started](#) - [customize your page](#)

Mixed Receptive-Expressive Language Disorder

93392 Drugs
1631 Developers
40 Indications
569 Conditions

Hot Topics

- [Activity](#)
- [Drugs](#)
- [Indications](#)
- [Up and Coming Indications](#)
- [CRO Activity Analysis](#)

Cancer

Non-Phenylketonuric Hyperphenylalaninemia

Hormonal Systems

Cardiovascular

Immune System

Central Nervous System

Dermatology

Musculoskeletal

Gastrointestinal

Nephrology

Genitourinary

Hematological

Featured report

Horizant Adverse Events Report


GSK/XenoPort's postherpetic neuralgia and restless legs syndrome drug Horizant received 184 adverse events.



Featured report

Onglyza and Kombiglyze XR Adverse Events Report

AstraZeneca's Onglyza/Kombiglyze XR receives 19 reports of cardiac failure.



Featured report

Novartis reports lung cancer patients respond to drug in study

Non-small cell lung cancer had responded to the treatment,

